---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-325370"
form_type: "8-K"
ticker: "SYBX"
cik: "0001527599"
company_name: "SYNLOGIC, INC."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T09:52:41.495290+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Synlogic reports Q3 net loss $16M; PKU Phase 2 shows proof of concept, moving to Phase 3

## Summary
- Interim Phase 2 SynPheny-1 data: SYNB1618 achieved proof of concept with statistically significant Phe reduction in PKU patients.
- SYNB1934 showed 2x improvement in Phe metabolism biomarkers vs SYNB1618; Phase 3 start planned in 2022.
- Cash, equivalents and short-term investments $150.1M as of Sept 30, 2021; net proceeds $48.4M from public offering.
- Revenue $0.9M from Roche IBD collaboration; first milestone payment earned; no further SYNB1891 studies planned.
- Net loss $16.0M ($0.29/share) vs $13.2M ($0.36/share) in Q3 2020; R&D expense $13.4M, G&A $3.6M.

## SEC filing metadata
- accession: 0001193125-21-325370
- form_type: 8-K
- ticker: SYBX
- cik: 0001527599
- company_name: SYNLOGIC, INC.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527599/000119312521325370/0001193125-21-325370-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527599/000119312521325370/d259422d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-325370
- JSON: https://secwatch.observer/filing/0001193125-21-325370.json
- Plain text: https://secwatch.observer/filing/0001193125-21-325370.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.